Cutler Group LP Cel Sci Corp Call Options Transaction History

Cutler Group LP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2021 Jan 18, 2022	SELL	$7.1 - $12.82 $302,460 - $546,132	-42,600 Reduced 93.42%	3,000 $0
Q3 2021 Oct 26, 2021	SELL	$7.64 - $12.49 $797,616 - $1.3 Million	-104,400 Reduced 69.6%	45,600 $19,000
Q2 2021 Jul 19, 2021	BUY	$8.68 - $27.49 $803,768 - $2.55 Million	92,600 Added 161.32%	150,000 $19,000
Q4 2020 Jan 21, 2021	BUY	$11.05 - $16.62 $264,095 - $397,218	23,900 Added 71.34%	57,400 $55,000
Q3 2020 Oct 27, 2020	BUY	$11.69 - $14.54 $376,418 - $468,188	32,200 Added 2476.92%	33,500 $15,000
Q2 2020 Jul 22, 2020	SELL	$9.75 - $17.6 $3,900 - $7,040	-400 Reduced 23.53%	1,300 $6,000
Q1 2020 May 07, 2020	SELL	$7.54 - $17.05 $70,122 - $158,565	-9,300 Reduced 84.55%	1,700 $3,000
Q3 2019 Oct 28, 2019	BUY	$6.0 - $9.6 $66,000 - $105,600	11,000 New	11,000 $17,000

6.16M

16.6K

148K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $46.8M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.